TME Pharma announces completion of share consolidation

With the publication of this press release, i.e., after the share consolidation has taken effect, the total issued share capital amounts to €1,361,094 divided into 1,361,094 shares of € 1.00 each. Trading of the new shares with ISIN NL0015000YE1 on the Euronext Growth Paris market will commence on July 28, 2022, and reverse stock split settlement will take place on August 1, 2022.

The table below summarizes key remaining process steps and dates in the share consolidation process.

• Last trading day of the old shares –  July 27, 2022
• End of the 30-day parity period –  July 27, 2022
• Ex-Date, first trading day of the new shares –  July 28, 2022
• Last day of settlement of exercised option and conversion rights into old shares  –  July 28, 2022
• Record date  –  July 29, 2022
• Last day of the suspension period  –  July 29, 2022
• Settlement of the reverse stock split and first day of settlement of exercised option and conversion rights into new shares  –  August 1, 2022
• Payment proceeds of aggregated whole shares to holders of fractional entitlements  –  Expected before the beginning of September but subject to the market conditions and measures being followed by relevant brokers to maintain an orderly market. 

About the GLORIA Study

GLORIA (NCT04121455) is TME Pharma’s dose-escalation, Phase 1/2 study of NOX-A12 in combination with radiotherapy in first-line partially resected or unresected glioblastoma (brain cancer) patients with unmethylated MGMT promoter (resistant to standard chemotherapy). GLORIA further evaluates safety and efficacy of NOX-A12 three additional arms combining NOX-A12 with: A. radiotherapy in patients with complete tumor resection; B. radiotherapy and bevacizumab; and C. radiotherapy and pembrolizumab.

About the OPTIMUS Study

OPTIMUS (NCT04901741) is TME Pharma’s planned open-label two-arm Phase 2 study of NOX-A12 combined with pembrolizumab and nanoliposomal irinotecan/5-FU/leucovorin or gemcitabine/nab-paclitaxel in microsatellite-stable metastatic pancreatic cancer patients.

Disclaimer

Translations of any press release into languages other than English are intended solely as a convenience to the non-English-reading audience. The company has attempted to provide an accurate translation of the original text in English, but due to the nuances in translating into another language, slight differences may exist. This press release includes certain disclosures that contain "forward-looking statements.” Forward-looking statements are based on TME Pharma’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, the risks inherent in oncology drug development, including clinical trials and the timing of and TME Pharma’s ability to obtain regulatory approvals for NOX-A12 as well as any other drug candidates. Forward-looking statements contained in this announcement are made as of this date, and TME Pharma undertakes no duty to update such information except as required under applicable law.